Monitoring of amikacin-induced ototoxicity during the treatment of multidrug resistant tuberculosis

O. Ozturk, O. Tumer, O. Avci, N. Adiguzel, S. Oztas, H. Solak, M. Kurutepe (Istanbul, Turkey)

Source: Annual Congress 2002 - Drug resistance
Session: Drug resistance
Session type: Thematic Poster Session
Number: 2223
Disease area: Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
O. Ozturk, O. Tumer, O. Avci, N. Adiguzel, S. Oztas, H. Solak, M. Kurutepe (Istanbul, Turkey). Monitoring of amikacin-induced ototoxicity during the treatment of multidrug resistant tuberculosis. Eur Respir J 2002; 20: Suppl. 38, 2223

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Aminoglycoside ototoxicity monitoring in multidrug resistant tuberculosis: How much is enough?
Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment
Year: 2012

Amikacin treatment for multidrug resistant tuberculosis: how much monitoring is required?
Source: Eur Respir J 2013; 42: 1148-1150
Year: 2013


Shortened multidrug-resistant tuberculosis regimens overcome low-level fluoroquinolone resistance
Source: Eur Respir J, 49 (6) 1700223; 10.1183/13993003.00223-2017
Year: 2017



Treatment outcome of multi-drug resistant tuberculosis
Source: Annual Congress 2004 - Problems of resistance and HIV coinfection in tuberculosis
Year: 2004


Efficacy of empiric chemotherapy regimen in patients with multidrug resistant (MDR) tuberculosis
Source: Eur Respir J 2004; 24: Suppl. 48, 656s
Year: 2004

The surgery of multidrug resistant tuberculosis
Source: Eur Respir J 2003; 22: Suppl. 45, 556s
Year: 2003

Treatment possibilities of multi-drug resistant (MDR) tuberculosis
Source: Eur Respir J 2003; 22: Suppl. 45, 525s
Year: 2003

Comparison of moxifloxacin and ofloxacin in treatment of multidrug resistant pulmonary tuberculosis
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012

Safety and efficacy of linezolid, clarithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis
Source: Eur Respir J 2006; 28: Suppl. 50, 587s
Year: 2006

Treating multiple-drug resistant tuberculosis
Source: International Congress 2018 – PG13 Challenges in the treatment of tuberculosis
Year: 2018


Unit of multidrug resistant tuberculosis - effect of treatment
Source: Eur Respir J 2002; 20: Suppl. 38, 614s
Year: 2002

Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?
Source: Eur Respir J 2016; 48: 582-585
Year: 2016


Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB
Source: Eur Respir J 2009; 33: 581-585
Year: 2009



Treatment outcome of multidrug resistant tuberculosis with second line drugs
Source: Eur Respir J 2001; 18: Suppl. 33, 314s
Year: 2001

Outcome of multidrug resistant pulmonary tuberculosis
Source: Annual Congress 2010 - Tuberculosis drug resistance
Year: 2010


The efficacy of interferon-alpha in treating multi-drug resistant tuberculosis
Source: Annual Congress 2004 - Management of tuberculosis
Year: 2004


Outcomes of patients with multidrug resistant tuberculosis
Source: Eur Respir J 2005; 26: Suppl. 49, 652s
Year: 2005

A study on the clinical efficacy of a combination regimen with azithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis
Source: Eur Respir J 2004; 24: Suppl. 48, 722s
Year: 2004

Treatment of multidrug resistant pulmonary tuberculosis (MDR-TB) with different pattern of resistance
Source: Eur Respir J 2004; 24: Suppl. 48, 723s
Year: 2004

Clinical efficacy and safety of clarithromycin in the treatment of multi-drug resistant tuberculosis
Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance
Year: 2009